Acquisition

July 17, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Intimation of Acquisition of 2,35,512 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, on a preferential basis for consideration other than cash Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject; we, M/s Zota Health Care Limited (the “Company”), would like to inform you that the Company has acquired 2,35,512 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company (“WOS”), on a preferential basis for consideration other than cash, towards adjustment and discharge of the outstanding Unsecured loan together with outstanding accumulated interest thereto, granted by the Company to the WOS. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 are annexed herewith as (Annexure-1). This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl.: a/a Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 Annexure-1 Particulars Details Name of the target entity, details in brief such as size, i. Name of the Target Entity: Davaindia Health Mart turnover etc. Limited ii. Business of the Target Entity: To operate retail Generic Pharmacy chain under Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy. iii. Financial details: As per the audited financial statements for FY 2025-26, the turnover of WOS was Rs. 267.71 crores and the total paid-up share capital was Rs. 2.71 crores. Whether the acquisition would fall within related party The acquisition does not fall within related party transaction(s) and whether the promoter/ promoter group/ transactions. The promoter/ promoter group/ group group companies have any interest in the entity being companies do not have any interest in WOS and the said acquired? If yes, nature of interest and details thereof and transaction is done at arm’s length basis. whether the same is done at “arm’s length” Industry to which the entity being acquired belongs Pharmaceutical Objects and effects of acquisition (including but not limited The Company has acquired 2,35,512 equity shares of WOS to, disclosure of reasons for acquisition of target entity, if its on a preferential basis amounting to Rs. 1,19,52,23,400/- business is outside the main line of business of the listed for consideration other than cash, through conversion of entity); outstanding Unsecured loan together with outstanding accumulated interest thereto, granted by the Company to the WOS. The said investment would result into reduction in Group’s total outstanding debt on a consolidated basis and improves overall net worth of the Group. Brief details of any governmental or regulatory approvals N.A. required for the acquisition Indicative time period for completion of the acquisition On July 17, 2026, the Company has acquired the 2,35,512 equity shares of WOS on a preferential basis for consideration other than cash. Nature of consideration - whether cash consideration or Conversion of outstanding Unsecured loan granted by the share swap and details of the same; Company to the WOS together with outstanding accumulated interest thereto, into equity shares of WOS on a preferential basis for consideration other than cash. Cost of acquisition or the price at which the shares are Cost of acquisition for 2,35,512 equity shares is Rs. 5,075/ acquired per equity share (including premium of Rs. 5,065/-) aggregating to Rs. 1,19,52,23,400/- through conversion of outstanding Unsecured loan together with outstanding accumulated interest thereto, in the books of accounts as stood at June 15, 2026. Percentage of shareholding / control acquired and / or The Company has acquired 2,35,512 equity shares of WOS. number of shares acquired Post to this acquisition, M/s Davaindia Health Mart Limited continues to remain as the Wholly Owned Subsidiary of the Company. Brief background about the entity acquired in terms of M/s Davaindia Health Mart Limited was incorporated on products/line of business acquired, date of incorporation, January 01, 2020, domiciled in India; operating COCO history of last 3 years turnover, country in which the acquired stores of Davaindia Generic Pharmacy with 1,855 stores as entity has presence and any other significant information (in at June 30, 2026 and offering 2000+ SKUs inclusive of brief) Medicines, Ayurvedic, Cosmetics, Nutraceutical and OTC products. During last three financial years, the details of turnover of WOS were as follows: FY 2025-26 Rs. 267.71 crores FY 2024-25 Rs. 109.93 crores FY 2023-24 Rs. 44.77 crores